Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
13.55
+0.24 (1.80%)
At close: Oct 31, 2025, 4:00 PM EDT
14.10
+0.55 (4.06%)
After-hours: Oct 31, 2025, 7:45 PM EDT
Phathom Pharmaceuticals Revenue
Phathom Pharmaceuticals had revenue of $49.50M in the quarter ending September 30, 2025, with 202.74% growth. This brings the company's revenue in the last twelve months to $147.19M, up 460.30% year-over-year. In the year 2024, Phathom Pharmaceuticals had annual revenue of $55.25M with 8,001.47% growth.
Revenue (ttm)
$147.19M
Revenue Growth
+460.30%
P/S Ratio
6.65
Revenue / Employee
$344,707
Employees
427
Market Cap
943.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55.25M | 54.57M | 8,001.47% |
| Dec 31, 2023 | 682.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
PHAT News
- 1 day ago - Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease - GlobeNewsWire
- 8 days ago - Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting - GlobeNewsWire
- 11 days ago - Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 - GlobeNewsWire
- 25 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 25 days ago - Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer - GlobeNewsWire
- 2 months ago - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire